LE051
Phase 1Small molecule
LE051 is one of 25 small molecule programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Coreg
Akero TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Garamycin
SSchering-Plough
Approved
Advil
KKenvue Brands
Approved
Rifadin
SanofiPhase 3
Duvyzat
ItalfarmacoPhase 3
Vyondys 53
Sarepta TherapeuticsApproved
Agamree
CCatalyst Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LE051. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details